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The clinical research industry involves multiple entities working to provide 
evidence that hopes to bring new treatments that benefit the general public. Each entity 
has their respective goals to navigate and contributions to ensure that research subjects 
are safe during their participation in clinical trials. In the history of clinical research, there 
have been reports of research misconduct, where the interests of the participants were 
not of the utmost priority. The government has created new regulations and institutions 
have implemented procedures to ensure that risks of misconduct are mitigated. 
The author examined the connection between stakeholders involved in the 
clinical research enterprise, and their respective roles and goals. These stakeholders 
include the sponsor, contract research organizations, principal investigators, and the 
research institution. At the center of the complementary entities are the patients that put 
their trust in the clinical research system to give themselves hope and contribute to and 
advocate for clinical research. Adult oncology Principal Investigators, Leaders, and 
Research Staff at the author’s community hospital research practice graciously 
contributed to the conduct of this Capstone Project by completing a questionnaire 
assessing their needs and perceptions. There were areas identified for further 
investment within the institution’s clinical research infrastructure. The author offered 
operational enhancements for the institution to implement and created a Sponsor 
Qualification Tool that will empower clinical research sites to determine if a sponsor and 




Table of Content 
Abstract………………………………………………………..………………………….   ii 
 










Acknowledgements………………………….………..………,,…….………………….  ix 
 
Chapter 1. Introduction………….…….…….………………………………………….  1 
1.1. Background…………………………..……………………………………………….  1 
1.2. Statement of the Problem…………………………………………………………… 2 
1.3. Project Question(s)………………………..…………………………………………. 2 
1.4. Project Objectives………………………..……………………….……………...….. 3 
1.5. Significance.………..………………………..…………………….………………….  4 
1.6. Exclusions and Limitations………..………….…………….…….…………………. 4 
 
Chapter 2. Literature Review…………………..………………….…………………... 6 
2.1. Overview of Literature Review……………………………………………………... 6 
2.2. Details of Review……………………………..………….……...…………………. . 6 
2.2.1. Code of Federal Regulations…………………………..….…....…………… 6 
2.2.2. The False Claims Act……………..…………….…...…….….……..……….  8 
2.2.3. ICH-GCP……………………………………………….…...………..……….. 9 
2.2.4. Contract Research Organization………………………….……...………… 9 
2.2.5. Research Misconduct………..……………………….……….…………..…. 10 
 2.2.5.1. Issues with Informed Consent……….……….…………..………….. 10 
2.2.5.2. Investigator Research Misconduct……………….…………..…..…. 11 
2.2.5.3. Sponsor Misconduct………….…………………….…………..…….. 15 
2.2.5.4. Contract Research Organization Misconduct…….……...……….. . 16 
2.3. Applicability of Literature Review…………………………..………………………. 17 
 
Chapter 3. Need(s) Assessment…….….…………..……..……..…………………… 18 
3.1. Need(s) Assessment……………………………….…..………….………………... 18 
3.1.1. Assessment of Need…………………….…..………………………………… 18 
iv 
 
3.2. Metrics…………...…………….……………….………………..………….……..…. 19 
3.3. Sources….…………..………………………………………………………………… 19 
3.4. Committees…..…………...….……………….…………..………………..………… 19 
3.5. Committee role.…………………………..…….……………………….……………. 19 
 
Chapter 4. Project Description………….…………..……..……..………………..…. 20 
4.1. Project Elements….……………………………….…..………..………………..…. 20 
4.1.1. Project Questionnaire……………………………….………..………………. 20 
4.1.2. Sponsor Qualification Tool Development……..………..……………..……. 20 
 
Chapter 5. Methodology………………….…………..……..……..………………..…. 22 
5.1. Methodology Overview…...……………………….…..………..…………………... 22 
5.2. Project Design and Discussion..…………….………………..……….…………… 22 
 5.2.1. Questionnaire Distribution….………………..……….……………………… 24 
5.3. Discussion of Questionnaire….…..………….…………..……………….………… 24 
5.3.1. Demographics Items……..……………….……………..…...……..…….…. 24 
5.3.2. Multiple Choice Items…………..……..……………..……….………………  25 
5.3.3. Free-response Items…………..……..……………..………..………..…….. 28 
 
Chapter 6. Project Results and Discussion..……..……..……..…………………..  29 
6.1. Questionnaire Results…...………………………..…..………..…………………..  29 
 6.1.1. Results per Question…………………...……………………………………. 31 
 
Chapter 7. Recommendations and Discussion..……..………..………………….  39 
7.1. Introduction…………...……………………….…..………..………………………..  39 
7.2. Recommendations………...……………………….…..………..………………….  39 
7.2.1. Operational Observations and Recommendations…..….…………..……  39 
7.2.1.1. Recommendation 1: The Institution should re-examine how PI 
and Research Leaders are Trained and Retool the Training so that PIs and 
Research Leaders can Improve their Effectiveness……………………..…. 39 
7.2.2. Concerns about clinicians pursuing off-label usage of drugs without IRB 
and FDA oversight…………………………………………………………………… 41 
7.2.1.1. Recommendation 2: The Institution Should Have a Research 
Integrity Officer (RIO) that is Dedicated Solely to Investigating Allegations 
of Research Misconduct…………………….………………………..………… 41  
 7.2.3. Lack of Institutional support for clinical research………………………….. 42 
 7.2.3.1. Recommendation 3: The Institution Should Listen to its Internal 
 Research Stakeholders and Become Well-poised to Continue Developing 




 7.2.4. Further enhancements to the existing compliance and quality assurance 
 efforts………………………………………………………………………………….. 43 
 7.2.4.1. Recommendation 4: The Institution Should Have a Quality 
 Assurance Team Specific to the Adult Oncology Department….………….. 43 
7.2.5. Sponsor & CRO Goals and Discussion………..…..……..…………..……  44 
7.2.6. Patient Focus…………………………………………………………………  46 
7.2.7. Unilateral study initiation process does not verify sponsor qualifications. 48 
7.2.7.1. Recommendation 5: Propose a Sponsor Qualification Tool to  
Examine the Sponsor’s & CROs Ability to Support the Site Throughout  
the Conduct of the Clinical Trial………………………………………………. 48 
 
Chapter 8. Conclusion …………………………………………………………………. 52 
 
Bibliography…………....………………….…………..……..……..……….………….  54 
 
Appendix 1: Questionnaire...………………………..……..……..….….…………….  57 
 
Appendix 2: Email Script……………………..……..……..……..….….…………….  62 
 
Appendix 3: Sponsor Qualification Tool…..……..……..……..….….…………….  64 
 
Appendix 4: Homewood Institutional Review Board Acknowledgement……..  67 
 
Appendix 5: Orlando Health Institutional Review Board Exemption....……….  69 
 





Figure 1. Relationships Between Clinical Research Stakeholders…..…………. 3 
Figure 2. Number of Clinical/ PI & Leadership Respondents.……….…..…...…. 29 
Figure 3. PI & Leader Responses for Effective Institutional Training…...….…. 32 
Figure 4. Responses for Pressure to Enroll Among Research Staff...…....…… 32 
Figure 5. Responses for Pressure to Enroll Among PI’s & Leaders.…………... 33 
Figure 6. PI & Leader Pressure to Complete Unrelated Tasks………....…….…. 34 
Figure 7. PI & Leader Reports of Effective External Training...…………………. 35 
Figure 8. Research Staff Report of Effective External Training.…..…………..... 35 
Figure 9. Responses for Partners are Responsive to Site Needs………………. 36 
Figure 10. PI & Leader Response: Patient Needs vs Protocol Deviation………. 37 
Figure 11. Research Staff: Patient Needs vs Protocol Deviation………….……. 37 
Figure 12. Responses for Effective Partnerships that Benefit Patients…….…. 38 
 
Tables 











ACRP  Association of Clinical Research Professionals 
CFR  Code of Federal Regulations 
BCC  Blind Carbon Copy 
CORO Corporate Office of Research Operations 
CRA  Clinical Research Associate 
CRC  Clinical Research Coordinator 
CRO  Contract Research Organization 
FCA  False Claims Act 
FDA  Food and Drug Administration 
GCP  Good Clinical Practice 
ICH  International Conference on Harmonization 
IND  Investigational New Drug 
IRB  Institutional Review Board 
NDA  New Drug Application 
PHI  Protected Health Information 
PI  Principal Investigator 
RIO  Research Integrity Officer 
RVU  Relative Value Units 
SD  Standard Deviation 






Informed Consent. According to the Food and Drug Administration, “the informed  
consent process involves three key features: (1) disclosing to potential research 
subjects information needed to make an informed decision; (2) facilitating the 
understanding of what has been disclosed; and (3) promoting the voluntariness 
of the decision about whether or not to participate in the research. Informed 
consent must be legally effective and prospectively obtained.”1 
 
Relative Value Units. “Medicare uses a physician fee schedule to determine payments  
for over 7,500 physician services. The fee for each service depends on its 
relative value units (RVUs), which rank on a common scale the resources used 
to provide each service. These resources include the physician’s work, the 
expenses of the physician’s practice, and professional liability insurance.”2 
 
Research Misconduct. The Office of Research Integrity of the Department of Health &  
Human Services defines research misconduct as “fabrication, falsification, or 
plagiarism in proposing, performing, or reviewing research, or in reporting 
research results”3  
 
Standard Deviation. Standard deviation in statistics, typically denoted by σ, is a  
measure of variation or dispersion (refers to a distribution's extent of stretching or 
squeezing) between values in a set of data. The lower the standard deviation, the 
closer the data points tend to be to the mean (or expected value), μ. Conversely, 








1. Informed Consent FAQs, Office for Human Research Protections, Department of Health and Human Services, accessed October 
11, 2020, https://www.hhs.gov/ohrp/regulations-and-policy/guidance/faq/informed-consent/index.html 
2. “Relative Value Units (RVUs)”. National Health Policy Forum, January 12, 2015, https://www.nhpf.org/library/the-
basics/Basics_RVUs_01-12-15.pdf 
3. “Definitions of Research Misconduct”. Office of Research Integrity, accessed October 4, 2020, https://ori.hhs.gov/definition-
research-misconduct 
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Chapter 1. Introduction 
1.1. Background. 
Clinical research is “research in which people, or data or samples of tissue from 
people, are studied to understand health and disease. Clinical research helps find new 
and better ways to detect, diagnose, treat, and prevent disease.”1  A clinical trial is a 
research study in which one or more human subjects are prospectively assigned to one 
or more interventions (which may include placebo or other control) to evaluate the 
effects of the interventions on biomedical or behavioral health-related outcomes.”2 
Clinical Research Sites, Sponsor, and Contract Research Organizations (CROs) 
each have their role to fulfill within the clinical research enterprise. A research site is an 
institution where Human Subjects research is conducted.3 Research sites recruit 
patients and maintain certain quality measures to ensure that the patients are safe 
throughout their participation. A sponsor is the organization or investigator “who initiated 
the study and who has authority and control over the study.”4 A CRO is “a company 
hired by another company or research center to take over certain parts of running a 
clinical trial. The company may design, manage, and monitor the trial, and analyze the 
results.”5 Clinical research has many different players and phases of a project, and all of 
the stakeholders must trust each other and communicate their needs throughout the 
research process.  
____________________ 
1. NCI Dictionaries, s.v. “Clinical Research,” accessed September 28, 2020, 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/clinical-research 
2. 45 CFR 46.102 
3. Ibid. 
3. Glossary of Common Site Terms, s.v. “Sponsor,” accessed September 18, 2020, https://clinicaltrials.gov/ct2/about-
studies/glossary 






1.2. Statement of the Problem. 
 These stakeholders have a duty to function together to push Investigational New 
Drugs (IND) to the marketplace, and to benefit patients with new effective treatments 
against such diseases as cancer. These same goals can also cause an unbalance 
within the separate entities, creating the potential for research misconduct if there is 
nothing to preempt fabrication (“making up data or results and recording or reporting 
them”)6, falsification (“manipulating research materials…or changing or omitting data or 
results such that the research is not accurately presented in the research record”)7, or 
plagiarism (appropriation of another person’s ideas, processes, results, or words without 
giving proper credit”)8 in clinical research conduct and reporting. 
1.3. Project Question. 
Due to the increasingly complex operational structure of clinical research and the 
multitude of risks that each stakeholder navigates, what are the perceptions of site 
investigators and staff, and how do they navigate these risks? What are the mitigating 
factors that protect principal investigators (PIs), research sites, sponsors and CROs 
from conducting misconduct in the course of their research? How do PIs, research site 
leaders and staff feel about their operations, and their interactions with sponsors and 
Contract Research Organizations? How can a research site standardize communicating 
their expectations to the external partners prior to study initiation? These are some of 
the questions the author of this Capstone Project will be addressing. 
____________________ 





















Research participants in this Capstone project will be given an opportunity to report their 
own perceptions on the research site’s operations, and how effective they feel their 
relationship is with sponsors and CROs. 
1.5. Significance.  
There is currently sparse data examining the perceptions of clinical research 
practitioners in community oncology research regarding their internal practices and their 
relationships with Sponsors and Contract Research Organizations. This investigation 
will provide insight into the comprehensive interplay between the stakeholders, and how 
each stakeholder is responsible for their own conduct and monitoring others’. 
Historically, sponsors and CROs conduct unidirectional Site Qualification Visits to 
assess a potential research site’s ability to conduct their trial. The author will develop a 
tool for sites to use to vet the Sponsor’s and CRO’s ability to support the site during the 
conduct of the trial. 
1.6. Exclusions and Limitations. 
 For the purposes of this Capstone Project, the scope of the project includes data 
from clinical research stakeholders from a community hospital with an oncology 
department that currently runs over 170 clinical research studies. A questionnaire 
inquiring about clinical research goals and expectations was distributed to internal 
employees within an Adult Oncology practice. The clinical research stakeholders 
include principal investigators, research staff comprising of clinical research 
coordinators, regulatory coordinators, and data management staff, and leaders from the 
adult oncology and compliance divisions. The hospital contains a research compliance 
office with its own Institutional Review Board. The questionnaire was not distributed to 
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representatives of sponsors or Contract Research Organizations, so these opinions and 
perceptions are not present in the author’s analysis. Collection of this important data is 
a limitation of this project. Further research is needed to seek the perceptions of agents 
from Sponsors and CROs to understand how they perceive their relationships among 





Chapter 2. Literature Review 
2.1. Overview of Literature Review. 
The literature reviewed for this project includes the Code of Federal Regulations, 
the False Claims Act and The International Conference on Harmonization E6 Good 
Clinical Practice (ICH-GCP) guidance. The ICH-GCP was created to standardize 
research practice in the European Union, the United States, and Japan. These sources 
both govern and seek to mitigate the risks inherent in research conduct for all parties 
involved in human subjects research. All stakeholders in the research enterprise are 
required to have working knowledge of the regulations and guidance documents and 
receive periodic training to ensure compliance. 
There is a limited amount of literature examining the role of Contract Research 
Organizations and their interactions with Sponsors and clinical research sites where 
human subjects research is conducted.  
2.2. Details of Review. 
2.2.1. Code of Federal Regulations. 
The Code of Federal Regulations (CFR) are housed within the Federal Register 
of the United States government. Several of these CFR are central tenets to the 
practice of clinical research and protections for clinical research subjects. Title 21 Food 
and Drugs, Chapter 1 Food and Drug Administration, Department of Health and Human 
Services, Subchapter A General, Part 50 Protection of Human Subjects defines a 
“clinical investigation [as] any experiment that involves a test article and one or more 
human subjects.”10 An investigator is “an individual who actually conducts a clinical  
____________________ 




investigation, i.e. under whose immediate direction the test article is administered or 
dispensed to, or used involving, a subject, or, in the event of an investigation conducted 
by a team of individuals, is the responsible leader of that team.”11 The team may consist 
of sub-investigators, clinical research coordinators, data management personnel, and 
regulatory support staff. A “human subject means an individual who is or becomes a 
participant in research, either as a recipient of the test article or as a control. A subject 
may be either a healthy human or a patient.”12 This CFR is particularly important due to 
the Informed Consent requirements that are written. It details elements that informed 
consent must contain, and what provisions exist when informed consent is not feasible 
and an investigational product must be implemented. 21 CFR 50 also contains rules 
that Institutional Review Boards (IRBs) must follow. An IRB is a “board, committee, or 
other group formally designated by an institution to review biomedical research involving 
humans as subjects, to approve the initiation of and conduct periodic review of such 
research.”13 
 Another central CFR is Title 45 Public Welfare, Subtitle A Department of Health 
and Human Services, Subchapter A General Administration, Part 46 Protection of 
Human Subjects. 45 CFR 46 contains the Common Rule under Subpart A, Basic HHS 
Policy for Protection of Human Research Subjects.14 This describes the types of 
research that do not fall under the coverage of the policy. There is also a list of research 
activities that would not require informed consent. For the purposes of clinical research 
that tests investigational products on humans, the policy does apply. 45 CFR 46  
____________________ 
11. 21 CFR 50  
12. Ibid. 
13. Ibid. 
14. 45 CFR 46 
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describes the structure of an IRB and how they must operate and review different 
categories of research under the regulations. Informed consent is also covered under  
this regulation, so the gravity of proper informed consent is apparent to investigators. 45 
CFR 46 also provides policies for involvement of vulnerable populations in clinical 
research. These include research involving pregnant women or fetuses, neonates, 
prisoners, and children. These regulations are to ensure that these participants are 
greatly protected and that no coercion occurs as a result of their vulnerable status.  
2.2.2. The False Claims Act. 
 The False Claims Act (FCA) “was enacted in 1863 by a Congress concerned that 
suppliers of goods to the Union Army during the Civil War were defrauding the Army. 
The FCA provided that any person who knowingly submitted false claims to the 
government was liable for double the government’s damages plus a penalty.”15 Since its 
inception there have been changes to the Act increasing the damages and penalties 
that violators must pay.16 The liability under FCA applies to “any person who knowingly 
presents, or causes to be presented, a false or fraudulent claim for payment or 
approval; [or] knowingly makes, uses, or causes to be made or used, a false record or 
statement material to a false or fraudulent”.17 Per the US Code a person who knowingly 
commits applicable activities is one that “has actual knowledge of the information; acts 
in deliberate ignorance of the truth or falsity of the information; or acts in reckless  




15 False Claims Act, 31 U.S.C. §§ 3729 – 3733, accessed September 30, 2020, 
https://www.justice.gov/sites/default/files/civil/legacy/2011/04/22/C-FRAUDS_FCA_Primer.pdf 
16. Ibid. 
17. False Claims, False Claims Act, 31 U.S.C. §§ 3729(a)(1)(A-B), accessed September 30, 2020, 
https://www.justice.gov/sites/default/files/civil/legacy/2011/04/22/C-FRAUDS_FCA_Primer.pdf 




 In clinical research, the ramifications of false claims are widespread and severe; 
fraudulent publications may arise and the public may be exposed to potentially harmful 
substances that have not been proven to be effective and safe. 
2.2.3. ICH-GCP. 
 The Good Clinical Practice guidance was created under international 
collaboration between the European Union, the United States, and Japan to guide 
clinical research conduct to conform to a standard practice for “designing, conducting, 
recording and reporting trials that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and 
well-being of trial subjects are protected…and that the clinical trial data are credible.”19 
The new addendum E6(R2) is a comprehensive document that contains guidance for 
investigators, research sites, monitors, and sponsors.20 While the recommendations in 
the document are not codified into the federal regulations, the suggestions presented 
are a beacon of practices that the Food and Drug Administration within the Department 
of Health and Human Services provides as a reference document for clinical research 
practitioners. 
2.2.4.  Contract Research Organization. 
A Contract Research Organization (CRO) is “a company hired by another 
company or research center to take over certain parts of running a clinical trial. The 
company may design, manage, and monitor the trial, and analyze the results.”21 
According to Roberts, Kantarjian and Steensma, “high-quality CROs have the potential 
____________________ 
19. GUIDANCE DOCUMENT E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). 2018. Retrieved from: 
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-
e6r1  
20. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). FDA (2018). https://www.fda.gov/media/93884/download 




to add substantial benefit to the clinical trial process, including improving the quality of 
data collection and trial standardization.”22 CROs were initially created to meet an 
increasing need from the National Cancer Institute and pharmaceutical companies. 
They “were searching for ways to address rising research and development costs, 
including detailed required for New Drug Application submission to regulatory agencies 
such as US Food and Drug Administration (FDA)…CRO outsourcing provided ‘spillover 
capacity’ for data management and biostatistical analysis during peak activity periods, 
when the pharmaceutical companies’ own employees had insufficient capacity to 
complete all necessary tasks.”23 Due to this delegation of operations to a third party, 
there is a “question whether CROs as currently constituted add an unnecessary layer of 
complexity to a clinical trial process already burdened by bureauocracy.”24 Another 
issue within CROs is the attrition rate among their monitors. “The frequent high turnover 
rate [is] noted for monitors (due to their relatively low pay and often-cited desire to be 
hired by a pharmaceutical company because such companies usually provide greater 
upward mobility and employee benefits than CROs).”25 
2.2.5. Research Misconduct.  
2.2.5.1. Issues with Informed Consent. 
 In the all-too recent history of clinical research, there have been egregious errors  
in the collection of informed consent. Informed consent ensures that the research  
subject fully understands the nature of the research, and that they agree to be subject to 
unapproved interventions. As is well-known in clinical research lineage, the Public  
____________________ 
22. Daniel A, Roberts, Hagop M. Kantarjan, and David P Steensma. “Contract Research Organizations in Oncology Clinical 
Research: Challenges and Opportunities”. Cancer, no. 122 (March 2016): 1476-82. https://doi.org/10.1002/cncr.29994 
23. Ibid. 




Health Service operated the Tuskegee experiments in which African American men who 
were infected with syphilis were denied standard treatment in order to study the natural 
history of the disease. The “men had agreed freely to be examined and treated. 
However, there was no evidence that researchers had informed them of the study or its 
real purpose. In fact, the men had been misled and had not been given all the facts 
required to provide informed consent.”26 Subjects were never given an opportunity to 
decline participation or withdraw from the study. The study was initiated in 1932 and did 
not end until 1970 after serious ethical issues with the study were uncovered.27  
The Nazi in Germany conducted many horrific experiments on their prisoners. 
“Scientists there also carried out so-called freezing experiments on prisoners to find an 
effective treatment for hypothermia. Prisoners were also used to test various methods of 
making seawater drinkable.”28 Josef Mengele infamously conducted research on twins. 
These Nazi studies eventually gave rise to the Nuremberg Code to ensure studies were  
completed only under the supervision of a qualified physician and that informed consent 
be administered to every research subject. 
2.2.5.2. Investigator Research Misconduct. 
 There are many examples of research misconduct arising from investigators 
falsifying or fabricating data or demonstrating egregious conflicts of interest. Below is a 
small sample of publicly available notices of research misconduct that have been 
prosecuted for diverse reasons. 
____________________ 
26. “The Tuskegee Timeline,” Centers for Disease Control, US Public Health Service Study at Tuskegee. Last modified March 02, 
2020, https://www.cdc.gov/tuskegee/timeline.htm 
27. Ibid. 





James Lieber from the University of California at Los Angeles,  
knowingly and intentionally falsified and fabricated follow-up interview, urine 
samples, and urine sample records of human subject study participants and 
entered such false and fabricated data into the study’s data base…the 
respondent fabricated interviews for 20 of the 53 interviews assigned to 
him…Aggravating factors included theft of $5180 for incentive payments to 
subjects and travel expenses.29 
 
The Office of Research Integrity ultimately prohibited Mr. Leiber from “contracting or 
subcontracting with any agency of the United States government”30 for a period of 3 
years after the notice. 
 Dr. Charles Nemeroff, previously a psychiatry chairman at Emory University, had 
failed to disclose earnings from GlaxoSmithKline for touting their drug Paxil to 
physicians, while managing “a multi-million dollar grant from the NIH to research drugs 
under development by Glaxo.”31 He had also told Emory that “he would earn less than 
$10,000 a year from GlaxoSmithKline to comply with Federal rules”, but would go on to 
earn nearly $200,000, leading to an investigation by a United States Senator and 
departure from Emory. In 2009, “while negotiating with [University of Miami] for a job, 
Nemeroff even dangled the possibility of a new funder for the school if he was hired.”32 
In the years since his chairmanship at the Department of Psychiatry at the University of 
Miami, he is currently chairman for the same at another academic institution. 
Dr. Piero Anversa, former lab director from Harvard Medical School and Brigham 
and Women’s Hospital, ran cardiac stem cell studies and allegedly falsified and/or 
fabricated data. “The hospital agreed to a $10 million settlement with the U.S. 
____________________ 
29. “Findings of research misconduct, PMC4259688.”  NIH Guide for Grants and Contracts. Accessed October 23, 2020, 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259688/ 
30. Ibid. 






government over allegations Anversa and two colleagues’ work had been used to 
fraudulently obtain federal funding.”33 Harvard and Brigham and Women’s Hospital have 
asked that Anversa’s work “be retracted from medical journals.”34 Anversa’s total 
number of retractions “would put him in the top 20 list of scientists with the most 
retractions in the world.”35 The article by Oransky and Marcus consider the ramifications 
to the scientific community at large, specifically what happens now “to work that was 
based on his work.”36    
In October 2020, the Department of Justice (DOJ) published a notice regarding 
Sami Anwar of Washington state. Anwar was sentenced “to a 340 month term of 
imprisonment for falsifying human clinical research trials in connection with a fraud 
scheme”37 he directed. “He was found guilty of 47 counts of wire fraud, mail fraud, 
conspiracy, fraudulently obtaining controlled substances, and furnishing false material 
information to the Drug Enforcement Administration.”38 He falsified research data on 
many different drugs tested for a large number of indications, and “the evidence at trial 
indicated that [he] and his companies received over $5.6 million dollars from the 
fraud.”39 The following excerpt from the DOJ details systemic violations of patient trust, 
data manipulation, and employee harassment.  
 
____________________ 
33. Ivan Oransky, and Adam Marcus, “Harvard and Brigham call for more than 30 retractions of cardiac stem cell research,” Stat, 




37. “Richland Business Owner Sentenced to More Than 28 Years in Federal Prison for Falsifying Human Clinical Research Trials,” 








Sami Anwar, who is not a licensed medical doctor, would pose as a doctor and 
forge the signature of the doctors he employed. In addition, over a dozen former 
employees of Sami Anwar testified that he directly instructed them to assist him 
in committing the fraud including falsifying medical records and data to admit 
dozens of ineligible research subjects; falsifying research data including electro-
cardiograms and vital signs, obtaining blood specimens from Sami Anwar’s 
employees or stealing them from unwitting medical patients of his medical center, 
disposing of study medications by shooting them down the drain and then falsely 
recording them as having been properly injected as required, dangerously 
hoarding opioids intended to be dispensed to study subjects, and fabricating 
required subject diary entries. 
According to the evidence presented at trial and at sentencing [he] not only 
directed the fraud but engaged in threats, retaliation, and intimidation in order to 
hide his crimes from drug companies, the FDA, which regulated human clinical 
trials in the United States, and law enforcement. 40 
 
This constitutes an extreme example of the violation of the principals of human 
subjects protections, which are enforced by multiple layers of oversight by investigators,  
Institutional Review Boards (IRB), clinical research associate monitors, and the  
sponsors themselves. At a minimum, clinical research studies are reviewed annually by  
an IRB to verify and ensure the safety of research subjects. Research monitors are sent 
by sponsors or contract research organizations (CROs) to periodically verify the 
accuracy of the data being collected and ensure that Good Clinical Practice guidelines 
are respected. With an extensive list of violations, the question of proper oversight 
remains. 
   
____________________ 
40. “Richland Business Owner Sentenced to More Than 28 Years in Federal Prison for Falsifying Human Clinical Research Trials,” 








2.2.5.3. Sponsor Misconduct. 
  Pharmaceutical company GlaxoSmithKline (GSK), in The United States v. 
GlaxoSmithKline lawsuit:  
Agreed to plead guilty and to pay $3 billion to resolve its criminal and civil 
liability arising from the company’s unlawful promotion of certain 
prescription drugs, its failure to report certain safety data, and its civil 
liability for alleged false price reporting practices…GSK agreed to plead 
guilty to a three-count criminal information, including two counts of 
introducing misbranded drugs, Paxil and Wellbutrin, into interstate 
commerce and one count of failing to report safety data about the drug 
Avandia to the Food and Drug Administration (FDA).41 
 
In the absence of safety data GSK published an article “that misreported that a clinical 
trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 
18.”42 The United States further accused GSK of sponsoring “dinner programs, lunch 
programs, spa programs, and similar activities to promote the use of Paxil in children 
and adolescents.”43 Also in violation of the False Claims Act, GSK promoted “asthma 
drug, Advair, for first-line therapy for mild asthma patients even though it was not 
approved or medically appropriate under these circumstances.”44 The U.S. also 
included “…allegations that GSK paid kickbacks to health care professionals to induce 
them to promote and prescribe these drugs as well as the drugs Imitrex, Lotronex, 
Flovent and Valtrex.”45 GSK also omitted detrimental cardiac safety data for its drug 
Avandia, according to the report. 
 
___________________ 
41. Office of Public Affairs, “GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report 









In a notice published by the Department of Justice in 2013, Johnson & Johnson 
and subsidiary Janssen,  
Allegedly promoted the antipsychotic drug [Risperdal] for use in children and 
individuals with mental disabilities… Nonetheless, one of Janssen’s Key Base 
Business Goals was to grow and protect the drug’s market share with 
child/adolescent patients. Janssen instructed its sales representatives to call on 
child psychiatrists…to market Risperdal as safe and effective for symptoms of 
various childhood disorders, such as attention deficit hyperactivity disorder, 
oppositional defiant disorders, obsessive-compulsive disorder and autism. Until 
late 2006, Risperdal was not approved for use in children for any purpose, and 
the FDA repeatedly warned the company against promoting it for use in 
children.46 
 
The DOJ report also details that they paid “kickbacks to physicians to prescribe 
Risperdal…[in] children, the elderly and those with developmental disabilities.”47 
 In the literature there are many other examples of misconduct from sponsors, but 
the cases above demonstrate those with some of the largest fines. The imprint of harm 
caused by these cases extends to vulnerable populations and represents a disregard 
for the protections regulations and GCP. 
  2.2.5.4. Contract Research Organization Misconduct. 
  There is little literature regarding CRO misconduct, though some 
examples can be found. Laura LaRosa, writing for the Association of Clinical Research 
Professionals (ACRP) describes one case, “where a CRA with 20 years of experience 
was doing her job properly in the field, only to have an in-house CRA with four years of 
experience try to make her change reports to fit the study protocol. The experienced 
CRA finally refused to sign the report.”48 In another example, “CRAs were consistently  
____________________ 
46. Office of Public Affairs, “Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations,” United 
States Department of Justice, November 4, 2013, https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-
criminal-and-civil-investigations 
47. Ibid. 





backdating, then often misfiling, interim visit follow-up letters.”49 These errors LaRosa 
says, “are probably generated by time pressures, internal political pressure to keep a 
study moving, and a lack of education and training.”50 
2.3. Applicability of Literature Review. 
 Investigators, research sites, sponsors and CROs all must follow regulations and 
laws to ensure patient safety and accurate data collection and reporting. There is an 
extensive history of human rights violations in clinical research. After these case 
histories of research misconduct, the government has taken steps to codify rules to 
enforce human subject protections, especially with populations that may be vulnerable 
to coercion or unable to decide for themselves whether to participate in a research 
study. Research institutions have initiated using training modules like the Collaborative 
Institutional Training Initiative (CITI) program to ensure their research staff is aware of 
the history of research, how to avoid misconduct, and consequences of non-
compliance. The manner in which investigators and clinical research staff perceive and 
navigate the internal operational layers of research bureaucracy and their interactions 
with sponsors and CROs are further examined in this project. The project will also report 
on preventative measures that have been instituted at a federal and institutional level to 











Chapter 3. Need(s) Assessment 
3.1. Need(s) Assessment. 
This Capstone Project is needed due to the lack of understanding how clinical 
research entities such as principal investigators, research sites, sponsors and Contract 
Research Organizations support a common goal of treating patients safely with new 
drugs, all while carrying their own long-term goals and expectations of the outcome of a 
project. These goals, if left un-checked, can lead to possible research misconduct. The 
main objective for principal investigators at research sites is to protect the patient, which 
may be at odds with the main objectives for the sponsor who is manufacturing the 
investigational product, and the CRO which is contracted to the sponsor. Expectations 
are clearly communicated by the sponsor and CROs to the research site, yet sites do 
not have a formal standardized mechanism to dictate their overall goals and 
expectations of Sponsor and CRO performance. 
3.1.1 Assessment of Need 
 The author conducted informal discussions with various principal investigators to 
gather their thoughts on risks and challenges inherent in conducting research at their 
facility. The author noticed trends in their topics, which included risks to themselves as 
the ultimately responsible party, and risks to the institution. The author then considered 
how principal investigators have general expectations of CROs and sponsors, and 
questioned how these are communicated during the conduct of a trial.  
Sponsors and CROs communicate their expectations of sites prior to initiating 
any research project, but the communication of site expectations is not reciprocal prior 
to accepting a sponsor’s study. A standardized tool for sponsor qualification is in order 




 No formal metrics were used to assess the need for this study. 
3.3. Sources. 
 The author is a clinical research coordinator who had informal conversations with 
oncology research principal investigators (PIs) regarding their perception of risk in 
conducting clinical research. The author then discussed the need to examine general 
clinical research stakeholder relationships with a PI.  
3.4. Committees. 
The author has not created a committee for guidance on this Capstone Project. 
The author has conferred with a physician-scientist who is the Director of the Center for 
Proton Therapy, Co-Chair of the Brain and Spine Tumor Center at the institution, and 
principal investigator in oncology research. This doctor is the author’s mentor on the 
Capstone Project. 
3.5. Committee Role. 
 The role of the mentor has been to guide the author in connecting concepts of 
risk and research misconduct that clinical research stakeholders encounter. They 
encouraged the author to maintain focus on the relationships between the institutions 
and how these relationships interplay to benefit the research patient. The mentor also 





Chapter 4. Project Description 
4.1. Discussion of project elements. 
 The Capstone Project is a multi-faceted endeavor combining human subjects 
regulations and guidance, examining the roles of clinical research stakeholders and how 
they all interact to serve the patient. Case studies of research misconduct conducted by 
principal investigators, sponsors and CROs are presented that represent unbalanced 
goals that do not value the patient as the central figure that they all serve.  
4.1.1. Project Questionnaire. 
This questionnaire assessed the perceptions of adult oncology clinical research 
principal investigators, department leaders, and research compliance office leaders and 
staff with regard to their relationships and experiences with sponsors and Contract 
Research Organizations. A questionnaire was administered to adult oncology leaders, 
principal investigators and adult oncology research staff from a community hospital that 
contains its own research compliance office and clinical research departments that 
focus on specific diseases including pediatric oncology, emergency medicine, pediatric 
cardiology, and orthopedics, among others. The questionnaire was submitted to and 
approved by the Johns Hopkins University Homewood Institutional Review Board (IRB), 
and the IRB at the author’s place of employment. 
 4.1.2. Sponsor Qualification Tool Development. 
Once the subject responses to the questionnaire had been analyzed for the 
elements that the site personnel reported, a tool was developed to facilitate the initial 
contact between research sites, the prospective study sponsor, and the CRO contracted 
to the sponsor. In the current pre-contract process, the sponsor conducts a Site 
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Qualification Visit with information that the site unilaterally must provide in order to 
prove their aptitude in conducting the research that the sponsor is offering. This tool 
provides the research site with qualifying information regarding the sponsor’s and 










Chapter 5. Methodology 
5.1. Methodology Overview. 
  
The author conducted a literature review of the human subjects regulations that 
all practitioners of clinical research must abide by. These standards are the framework 
by which institutional policies are written, and government granting agencies, sponsors 
and Contract Research Organizations are held to. Good Clinical Practice, a guidance 
document put forth by the International Conference on Harmonization is followed for its 
intent to standardize clinical research processes. Case studies of research misconduct 
arising from investigators, sponsors, and CROs were examined for their impact on 
patient safety and the impact to the scientific community. 
Prior to initiating a research partnership, sponsors ask potential clinical research 
sites for their qualifications, understandably to assess the feasibility of conducting a trial 
with minimal issues and risk to the outcome of the research they are proposing. The 
author has created a survey to assess a sponsor’s experience with conducting trials, 
and the infrastructure they have to assist sites from initiation to completion of a clinical 
trial. The hope is that this assessment will inform the institution of risk they assume in 
relying on sponsor and CRO processes.  
5.2. Project Design and Discussion.  
 Early in the development of the Capstone Project, the author planned to conduct 
a questionnaire with clinical research investigators at their institution. As directed in The 
Complete Guide to Writing Questionnaires51 the author conducted preliminary  
 
____________________ 
51. David F Harris, The Complete Guide to Writing Questionnaires: How to Get Better Information for Better Decisions (Durham, 




conversations with a small number of principal investigators (PI’s) to determine what 
their concerns were regarding the risks inherent in research conduct. The PI’s identified  
categories of risk: risk to the investigator, risk to the institution, and risk to the patient.  
This led the author to consider how clinical research stakeholders interact to accept and 
mitigate risk within the institution. Clinical research is conducted in partnership with 
sponsors and contract research organizations who are working with sponsors to 
oversee clinical trial operations. The author and Capstone Project mentor discussed the 
ongoing relationship between all of the entities, and how their efforts should ultimately 
benefit the research patient.  
In the history of clinical research there have been instances where the 
protections for human subjects were not honored, which has resulted in potential or 
actual harm to patients. The author conducted a literature review for instances of 
misconduct involving individual investigators and pharmaceutical companies. 
Documented research misconduct among contract research organizations was sparse.   
 With this information the author composed a questionnaire to assess the status 
of investigator perceptions of their relationship with sponsors and CROs. The author 
then considered the institution’s internal research team, ranging from department 
leaders, research administrators, coordinators, regulatory personnel, and data team, 
and how their input would be valuable for a well-rounded assessment. The Capstone 






5.2.1. Questionnaire Distribution 
The questionnaire titled Clinical Research Stakeholders’ Goals & Expectations 
was distributed with Blind Carbon Copy (BCC) to eligible participants via institutional 
email with an embedded link to the Google Form. The email contained an IRB-approved 
email script (please see Appendix 2: Email Script) which explained the purpose of the 
questionnaire and eligible participants’ rights as research subjects. One email was sent 
to eligible members of the Corporate Office of Research Operations (CORO), another 
email was sent to Adult Oncology Principal Investigators, and the last email was sent to 
Adult Oncology research staff. 
5.3. Discussion of Questionnaire. 
 The author composed a questionnaire that contained 14 items for respondents to 
complete anonymously. There were two demographics questions, and nine multiple 
choice items graded on a five-point Likert scale using Strongly Agree, Agree, Neutral, 
Disagree, Strongly Disagree as responses. Several items added a “Not applicable” 
option, since the eligible participants espoused either clinical or non-clinical roles. For 
the questionnaire in its entirety please see Appendix 1: Questionnaire. 
 5.3.1. Demographics Items. 
 The author had two questions that dealt with obtaining general demographic 
information. The question, How long have you worked in clinical research?, with 
response choices ranging from “11+ years; 6-10 years; 2-5 years; 0-1 year was asked in 
order to gauge the level of experience of the respondent and determine if the 
respondent had extensive or moderate experience at navigating clinical research 
regulations and conduct, or if they were a novice at conducting clinical research. If the 
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subject has many years of clinical research experience, they may have been exposed to 
instances of misconduct or lived through audit experiences that would have been an 
educational opportunity to them and the institution.  
In another question, What is your role at your institution? Select all that apply, a 
respondent could check a box to indicate what role they have at their institution. They 
could choose from the following roles: Leadership; Clinical/ Principal Investigator; or 
Research Staff. This question was asked to determine the perspective of the 
respondent with regard to their role at the institution. Those in leadership have an 
operational view of research conduct, including onboarding clinical trials, supervising 
clinical and research personnel, and contributing to the overall vision of the department. 
Principal investigators are responsible for the clinical care and risks of their patients and 
are ultimately responsible for the conduct of the trial. Research staff have varied roles, 
including clinical research coordination and project management, data management, 
regulatory document submission and tracking, and quality assurance. 
 5.3.2. Multiple Choice Items. 
There were nine multiple choice questions in the questionnaire with 5-point Likert 
Scale responses:  
‘My institution provides effective training on how to perform my role.’ This item 
assessed the subject’s perception on how the institution itself prepared them to perform 
their research role. The next item was, I feel pressure to enroll more patients into clinical 
trials, to reflect the potential of operational pressure to meet contractual accrual targets 
established at the initiation of a trial. “Not applicable” was included as a potential 
response. The institution is a member of the NRG cooperative groups within the 
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National Cancer Institute, which has an annual accrual target in order to maintain 
membership in the cooperative group.52 
In the third question, I feel pressure to get investigational drugs/ devices/ doses 
approved for ordinary care, respondents had Likert-scale responses to choose from, 
including “not applicable” as a choice for those that felt this statement did not apply to 
them. This question was asked to assess there was any pressure felt to have 
investigational products approved for standard of care uses, to assess whether this 
pressure could potentially overpower an investigator’s and institution’s equipoise in 
objectively studying an investigational agent.  
The fourth question asked, I have had concerns about clinicians pursuing off-
label usage of drugs without IRB and FDA oversight. Using a five-point “Adjectival 
Scale”53, the item assessed whether first-hand knowledge exists of investigators 
potentially using investigational unapproved products on patients without proper 
regulatory and human research protections.  
In the fifth multiple choice question, I feel pressure to complete tasks unrelated to 
conducting or reviewing research respondents could choose a 5-point Likert scale with 
the addition of “not applicable” for those that have no other roles competing for their 
time. The principal investigators at the author’s place of employment are also clinicians 
that see ordinary care patients. Those in leadership may have other administrative 
duties that require a considerable amount of effort apart from research conduct. 
____________________ 
52. “Membership requirements,” NRG Oncology, accessed October 18, 2020, https://www.nrgoncology.org/About-
Us/Membership/Membership-Requirements 
53. Spencer E Harpe, “How to analyze Likert and other rating scale data,” Currents in Pharmacy Teaching and Learning no. 7 




The questions that followed were assessing the perception of the subjects’ 
relationship with sponsors and CROs: 
I receive effective protocol-specific training from external research partners 
(Sponsors or Contract Research Organizations). This item used a 5-point Adjectival 
scale and a “not applicable” option for those that do not receive training from sponsors 
or CROs. The item was written to assess if the subjects find value in the extensive 
training that sponsors and CROs require for initiating effort on studies.  
The seventh question, External research partners (Sponsors or Contract 
Research Organizations) are responsive to my site’s needs, with a five-point Adjectival 
scale ranging from “Always” to “Never” was used to see if subjects felt these entities 
were helpful and perceived a reciprocal relationship with regard to managing study 
challenges. 
 The eighth multiple-choice question, Patient needs outweigh the need to adhere 
to the research protocol, even if it leads to a deviation, allowed respondents to choose 
from a five-point Likert Scale with available responses, “Strongly Agree, Agree, Neutral, 
Disagree, Strongly Disagree”, to tie the importance of patient safety in the clinician’s 
mindset to the requirements of adhering to protocol procedures. The statement seeks to 
identify if the subject places more importance on the patient rather than the 
requirements of the protocol. One of the most common findings in an FDA audit is 
“failure to follow investigational plan (34%)”54, however, some deviations involving the 
inability to conduct protocol procedures or follow dosing guidelines could be related to  
____________________ 
54. Sonia K Morgan-Linnell, David J Stewart, and Razelle Kurzrock. “U.S. Food and Drug Administration Inspections of Clinical 





immediate patient safety or situations that investigators cannot foresee. For the final 
multiple-choice question, My site has effective research partnerships that ultimately 
benefit the patient, respondents were able to choose from a five-point Agree Likert 
scale. This item attempts to tie the relationships with internal and external entities to the 
ultimate goal of benefiting the patient. 
 5.3.3. Free-response Items. 
At the latter part of the questionnaire, there are three free-response questions 
that allow the respondent to type in their response. These questions relate to multiple-
choice Items in the main section of the questionnaire:  
Please feel free to comment on the effectiveness of your relationship with external 
research partners (Sponsors & Contract Research Organizations);  
Please feel free to comment on any administrative challenges you encounter in your 
clinical research role; and 
Please feel free to comment on how your involvement in research benefits the research 
patient.  
With the free-response items, the authored hoped to solicit examples from the 








Respondents in the Clinical/ PI and leadership cohort all reported having greater than 6 
years of experience (6-10 years n=2; 11+ years n=9) in clinical research, with the 
exception of one respondent in a leadership role who self-identified as having 2-5 years 
of research experience. 69% of this cohort reported greater than 11 years of experience 
in clinical research. Respondents who self-identified as research staff, half (50%) 
reported they had between 2-5 years of experience (n=5); and up to 6-10 years of 
experience (n=5) in clinical research. 
 For the purposes of statistical analysis, responses were given a numerical value. 
Items using the Likert Scale ranged from 5 for “Strongly Agree”, 4 for “Agree”, 3 for 
“Neutral”, 2 for “Disagree”, 1 for Strongly Disagree, and 0 for “Not Applicable”. Items 
using an Adjectival Scale were assigned the following values for their responses: 5 for 
“Always”, 4 for “Very Often”, 3 for “Sometimes”, 2 for “Rarely”, 1 for “Never”, and 0 for 
“Not Applicable”. The scoring values facilitated the calculation of the statistical mean 
and standard deviation for the individual responses, as suggested by Harpe56 for 
analyzing Likert scales. Table 1. Assignment of Numerical Values for Scale Responses, 
demonstrates these values:  
Table 1. Assignment of Numerical Values for Scale Responses57 
Likert Scale Score Adjectival Scale 
Strongly Agree 5 Always 
Agree 4 Very Often 
Neutral 3 Sometimes 
Disagree 2 Rarely 
Strongly Disagree 1 Never 
Not Applicable 0 Not Applicable 
 
Response data was securely and anonymously collected via Google Forms. Once data  
 
____________________ 
56. Spencer E Harpe, “How to analyze Likert and other rating scale data,” Currents in Pharmacy Teaching and Learning no. 7 
(2015): 838, http://dx.doi.org/10.1016/j.cptl.2015.08.001 




collection was complete, all data was exported to a Microsoft Excel file. In the Excel file, 
data was sorted by Institutional Role, and responses were coded per the values shown 
in Table 1. The mean for each item was calculated (designated by μ) as well as the 
standard deviation (SD) of the responses (designated by σ). 
 6.1.1. Results Per Question. 
 The first question in the survey stated, My institution provides effective training 
on how to perform my role, and the responses were “Strongly Agree” to “Strongly 
Disagree” on a five-point Likert Scale. In the research staff cohort, the responses were 
overwhelmingly reported as “Agree” and “Strongly Agree”. There was only one 
response from a research staff member reported as “Neutral” The mean was μ=4.2, and 
SD σ=0.63. The mean corresponds to a response of “Agree”. 
In the Clinical/ PI and leadership cohort (n=13), responses provided insight into 
how the researchers and leaders felt about appropriate training provided by the 
institution. Question 3 prompted, My institution provides effective training on how to 
perform my role, with 5-point Likert scaled responses “Strongly Agree” to “Strongly 
Disagree”. Figure below shows the responses given, with responses distributed among 
the reported roles. Using the coded scores explained in Section 6.1.1 Table 1, μ=3.307, 
and σ=1.377. The mean corresponds to a response of “Neutral”.  Only 7/13 (53.8%) 
responded that they agreed or strongly agreed with this statement. Please see Figure 3. 
PI & Leader responses for effective Institutional training for a visual of how many 






Figure 3. PI & Leader responses for Effective Institutional Training58 
The second statement in the survey said, I feel pressure to enroll more patients 
into clinical trials, with 5-point Likert scale responses to select from either, “Strongly 
Agree, Agree, Neutral, Disagree, Strongly Disagree, Not applicable”. The responses 
were coded with numerical values per Table 1. The mean µ=1.8, which most closely 
represents “Disagree”, the mode (most reported response) was “Disagree”. The 
calculated SD σ =1.398 which describes the wider distribution of data present including 
the extreme lower end of the responses “Not Applicable”.  
 
Figure 4. Responses for Pressure to Enroll Among Research Staff59 
Among the Clinical/ PI’s and leaders, the data suggests that this cohort mostly does not  
 
feel pressure to enroll subjects, with the exception of one individual that holds a 
____________________ 
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Clinical/ PI role along with a leadership role; they chose “Strongly Agree”, as seen in 
Figure 5. below: 
 
Figure 5. Responses for Pressure to Enroll among PI’s & leaders60 
 
The mean µ=2.07 (corresponding to “disagree”) and SD σ=1.25. 
For the next statement in the questionnaire, I feel pressure to get investigational 
drugs/ devices/ doses approved for ordinary care, all of the respondents (n=23) in both 
cohorts combined answered either “neutral” 17.4%, “disagree” 39.1%, “strongly 
disagree” 30.4%, or “not applicable” 13%, µ=1.6, σ=0.94. 
The statement, I have had concerns about clinicians pursuing off-label usage of 
drugs without IRB and FDA oversight, most responses reported between “neutral”, 
“disagree” or “strongly disagree”. There were two respondents in the PI & Leadership 
cohort that responded “Agree”, one that was purely a PI, and the other had combined PI 
and Leadership roles. Among all subjects, the mean µ=1.82, SD σ=0.88.  
The next item on the questionnaire was I feel pressure to complete tasks 
unrelated to conducting or reviewing research. The responses were on an Adjectival 
scale; respondents had the option of choosing “Always, Very Often, Sometimes, 
____________________ 
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Rarely, Never”. The majority of the respondents chose “sometimes”, “rarely”, or “never”, 
µ=2.333, SD σ=1.302. One respondent in a leadership role selected “very often”, and 
the other in a combined PI and leadership role chose “always”, as seen in Figure 6. 
 
Figure 6. PI & Leader Pressure to Complete Unrelated Tasks61 
 
In the research staff cohort, 70% chose “strongly disagree”, while 20% selected 
“sometimes”, and 10% “not applicable”, mean µ=1.3 which corresponds to “strongly 
disagree, SD σ= 0.948. These results are unsurprising since the research staff are hired 
specifically to complete research-related tasks. 
 The following item, I receive effective protocol-specific training from external 
research partners (Sponsors or Contract Research Organizations), principal 
investigators and leaders had a wide distribution of responses, as demonstrated by the 
calculated mean µ=3.38, SD σ=1.6602. Figure 7. PI & leader reports of effective 
external training shows the responses: 
____________________ 
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Figure 7. PI & Leader Reports of Effective External Training62 
 
The research staff cohort had a calculated mean µ=4.2, which corresponds to “Agree”, 
with a SD σ=0.9189. As reported below in Figure 8, most responses were “strongly 
agree” or “agree”. 
 
Figure 8. Research Staff Report of Effective External Training63 
The next statement was External research partners (Sponsors or Contract 
Research Organizations) are responsive to my site's needs. The answers were on a 
____________________ 
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five-point Adjectival scale, with responses ranging from “Always” to “Never”. Using the 
entire set of responses (n=23), the mean µ=4, SD σ=0.738. The mean corresponded to 
the response “very often”. There were no responses for “strongly disagree” or “not 
applicable” as shown in Figure 9: 
 
Figure 9. Responses for Partners are Responsive to Site Needs64 
 
The penultimate item, Patient needs outweigh the need to adhere to the research 
protocol, even if it leads to a deviation, had respondents select from a 5-point Likert 
scale using “Strongly Agree” to “Strongly Disagree”. Among the PI & Leadership cohort, 
the mean µ=3.769, σ= 1.235. Figure 9. PI & Leader response: patient needs vs protocol 
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Figure 10. PI & Leader Response: Patient Needs vs Protocol Deviation65 
 
Among the research staff, the mean µ=4, and SD σ=1.1547. The mean of 4 
corresponds to a mean for the response “agree”. In Figure 11. Research staff patient 
needs vs protocol deviation, shows the wider distribution of responses for the research 
staff cohort, compared to responses to other items in the survey: 
 
Figure 11. Research Staff: Patient Needs vs Protocol Deviation66 
____________________ 
65. Carolina Manchola-Orozco, November 8, 2020. 
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This particular item on the questionnaire had a higher standard deviation in both 
cohorts, which demonstrates that the agreement with the statement is varied throughout 
the practice in all roles. 
The last item, My site has effective research partnerships that ultimately benefit 
the patient, had respondents select from “Strongly Agree” to “Strongly Disagree”. Figure 
12. Responses for effective partnership that benefit patients shows how 61% of the 
entire cohort chose “Agree”, 30% “Strongly Agree”, and 9% responded “Neutral”:  
 
Figure 12. Responses for Effective Partnerships that Benefit Patients67 
The calculated mean among all participants was µ=4.217, and the smallest SD of the 
entire survey σ=0.599. This particular result was pleasing to note that investigators, 
leaders, and research staff at large feel that the external partnerships with sponsors and 
contract research organizations benefit the patient. 
 
____________________ 
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Chapter 7. Recommendations and Discussion 
7.1. Introduction. 
 The questionnaire results have important observations with regard to PI, 
leadership, and research staff perceptions on their relationships with external clinical 
research stakeholders, and perceptions on the effectiveness of internal research 
infrastructure. Institutional policies and continuing education for staff are meant to 
protect against research misconduct. Sponsors and CROs each have their goals and 
expectations for their respective roles in the research enterprise, and all stakeholders 
have a responsibility to balance their goals with their collaborators’ goals in order to 
efficiently bring new therapeutics to market. To further assist the sites with initiating their 
relationship with sponsors and CROs, a Site Qualification Tool is proposed by the 
author to increase site engagement prior to contractually initiating a research 
collaboration. 
7.2. Recommendations. 
 7.2.1. Operational Observations and Recommendations. 
7.2.1.1. Recommendation 1: The Institution should re-examine how PI 
and Research Leaders are Trained and Retool the Training so that 
PIs and Research Leaders can Improve their Effectiveness. 
 The questionnaire collected observations from institutional research leadership, 
investigators, and staff that research leaders can consider in making operational 
improvements. The statement, My institution provides effective training on how to 
perform my role, had 38% of the PI’s and leaders either disagree or strongly disagree 
with that assertion. It would be helpful for the institution to re-examine how they train 
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their principal investigators (PIs) and research leaders and retool the training the 
institution can provide for this population to perform their role effectively. This 
questionnaire did not delve into the types of training or topics that would meet the needs 
of the investigators and leaders, so further inquiry would be helpful to address the 
training gap. If the institution is not able to provide their own educational programing for 
PIs and leaders, there are various professional organizations that are suited for training 
and certifying research investigators and administrators. The Association of Clinical 
Research Professionals (ACRP)68 has online coursework that serves to educate clinical 
researchers that are either entry, intermediate, or senior level, within a wide variety of 
topics including Good Clinical Practice, Quality Assurance, and leadership strategies. 
The ACRP offers certifications for research coordinators and research monitors, and a 
certification for Principal Investigators called Certified Principal Investigator (CPI). The 
Society of Research Administrators International (SRAI)69 is a professional organization 
that offers extensive training for research administrators and research leaders. One 
such training offered is a “Research Senior Executive Institute.”70 The data from 
research staff suggests that they receive appropriate training. This is a testament to the 




68. “ACRP Course Catalog,” Association of Clinical Research Professionals, 2020, https://acrpnet.org/training/ 








7.2.2. Concerns about clinicians pursuing off-label usage of drugs without 
IRB and FDA oversight. 
7.2.2.1. Recommendation 2: The Institution Should Have a Research 
Integrity Officer (RIO) that is Dedicated Solely to Investigating 
Allegations of Research Misconduct.  
With regard to the question that asked if respondents had concerns about 
clinicians pursuing off-label usage of drugs without IRB and FDA oversight, there were  
respondents from leadership that expressed concern. This question did not ask when 
these concerns occurred or if the concerns were still present, only if they had occurred. 
There is opportunity for further review of these instances which herald the potential for 
scientific misconduct. A recommendation for the institution would be to have a Research 
Integrity Officer (RIO) that is dedicated solely to investigating allegations of research 
misconduct. The ORI Handbook for Institutional Research Integrity Officers from the 
Office of Research Integrity of the US DHHS, is “a reference work for institutional 
officials who have responsibilities regarding the handling of allegations of scientific 
misconduct involving biomedical or research training.”71 
The “ORI also encourages institutions to adopt principles consistent with the 
Whistleblower Bill of Rights recommended by the Commission on Research Integrity 
and to foster institutional commitment to those principles.”72 Increasing training 
initiatives on whistleblower protections would be recommended for institutional 
adherence to the ORI. According to Bonito, Titus, and Wright, findings from a “study 
____________________ 
71. “ORI Handbook for Institutional Research Integrity Officers,” Office of Research Integrity, n.d., 
https://ori.hhs.gov/sites/default/files/rio_handbook.pdf 





found that 9% of PHS funded researchers reported observing possible research 
misconduct in the prior 3 years,”73 which is in alignment with the institution’s rate of 
concerned investigators in this sample. 
7.2.3. Lack of Institutional support for clinical research 
7.2.3.1. Recommendation 3: The Institution Should Listen to its 
Internal Research Stakeholders and Become Well-poised to  
Continue Developing its Clinical Research Venture.  
Institutional goals for research include having successful collaborations with 
sponsors which can lead to further collaboration and referrals to other sponsors. New 
research partnerships increase research-related funding and contracts with industrial 
pharmaceutical companies. Ultimately institutional reputation can elevate among the 
medical community, making the institution more competitive in recruiting top research 
talent and leadership. The institution has the ability to achieve prominence with its 
academically prolific oncology investigators. Commentary among the respondents 
of the questionnaire include the following from several that hold both Leadership and 
Principal Investigator roles: “I don’t think my institution values clinical research, in 
general, as much as other university based institutions. I sometimes feel the default 
answer is ‘no’, rather than ‘let me see what this is about.’”74 Another subject with dual 
leader and PI roles commented, “For most clinicians, there is no protected time to 
conduct research, which takes extra time. RVU [Relative Value Units] incentivized 
____________________ 
73. Arthur Bonito, Sandra Titus, and David Wright, “Assessing the Preparedness of Research Integrity Officers (RIOs) to 
Appropriately Handle Possible Research Misconduct Cases” Science and Engineering Ethics, 18 (2012): 605-619. 
https://doi.org/10.1007/s11948-011-9274-2 




physicians have a financial disincentive to enroll and take extra care of patients wrt [sic] 
documentation, etc.”75 In this community hospital setting, discussion should be 
considered to cease penalizing physician-scientists that wish to devote time to research 
activities and away from filling their clinic patient quota. A third leader/ PI exclaimed, 
“We are seeking a director position that will provide leadership to the team.”76 This is 
hopefully a harbinger of positive developments to come. One research staff member 
commented, “There is always room for growth and we can always do more to help our 
community by listening to the needs of our patients, physicians, and team members, 
come up with a process or a plan to expand our research vision and institution.”77 If the 
institution wishes, and is prepared to listen to its internal research stakeholders, it is 
well-poised to continue developing its clinical research venture. 
 7.2.4. Further enhancements to the existing compliance and quality  
 assurance efforts. 
7.2.4.1. Recommendation 4: The Institution Should Have a Quality 
Assurance Team Specific to the Adult Oncology Department. 
  The institution has a number of mechanisms that have been adopted to 
ensure regulatory compliance, and meet contractual obligations with regard to 
recruitment, subject safety reporting, and data quality. The institution has their 
own Institutional Review Board (IRB) that reviews and approves studies in adult and 
pediatric populations. Research staff, PIs and sub-investigators meet biweekly at 
minimum to discuss potential subjects, subjects undergoing active treatment, protocol  
____________________ 
75. Questionnaire respondent, October 23, 2020. 
76. Questionnaire respondent, November 2, 2020. 




deviations, serious adverse event reporting, and preparation for monitoring visits. This 
has created an environment where staff and clinical investigators are engaged and 
converse on important topics for their respective cancer types. There is also an 
institutional Quality Assurance initiative that employs internal auditors that review 
research documentation in all of the clinical research departments within the hospital. 
One suggestion the author offers is to have a Quality Assurance team specific to the 
adult oncology department, as there are two internal auditors for the entire institution. 
This initiative would add another layer of quality control for research subject data and 
regulatory documentation in addition to standard external monitoring visits. 
 7.2.5. Sponsor & CRO Goals and Discussion. 
 Sponsors control and design clinical research studies, and take “responsibility for 
the initiation, management, and/or financing of a clinical trial.”78 A sponsor can be an 
individual, or a pharmaceutical manufacturer of an investigational product. A sponsor 
can partner with pharmaceutical companies that allow them to use their investigational 
products, much like cooperative groups and scientists within the National Cancer 
Institute. “Before testing the product in the clinical phase, the sponsor should ensure 
that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are 
available to support human exposure by the route, at potential dosages, for the 
duration, and in the trial population to be studied.”79 In addition to reporting prior safety 
data,  
The sponsor is responsible for the ongoing safety evaluation of the 
investigational product. The sponsor should promptly notify all concerned 
____________________ 
78. Deepak Chilkoti. 2019. “Chapter 25: Stakeholders, Resources, and Documents in Clinical Research.” In Clinical Pharmacy 





investigators/institutions and the regulatory authority of findings that could affect 
the safety of subjects or alter the IRB/IEC’s [Independent Ethics Committee] 
approval opinion to continue the trial.80 
 
Sponsor goals are to develop compounds that may be shown to be effective in multiple 
indications in order to maximize return on their investment to develop an investigational 
product. As reported in section 2.2.5.3. Sponsor Misconduct, these goals have 
historically become unbalanced with sponsor greed and potentially harmed vulnerable 
populations by violations against the False Claims Act, or failure to report safety data 
that may lead a clinical trial to be halted or an approved product to be pulled from the 
market.  
CROs are contracted to sponsors to assist sponsors in managing clinical trial 
operations. As part of a CRO, Clinical Research Associates (CRA) have the following 
roles:  
managing approvals that oversee the research and marketing of new and 
existing drugs; identifying and assessing the suitability of facilities to be used as 
the clinical trial site; monitoring the trial throughout its duration; verifying that data 
entered… are consistent with patient clinical notes, source data/document 
verification; writing visit reports…; ensuring all unused trial supplies are 
accounted for…; archiving study documentation and correspondence”81 
 
As the research enterprise comes to terms with misconduct and Good Clinical Practice 
guidance, operational procedures seek to find equilibrium between hyper-regulation and 
lack of proper oversight. One item in the questionnaire asked subjects to comment on  
any administrative challenges they encounter in their clinical research role. One 
questionnaire respondent in a PI role shared, “The AE [adverse event] reporting and 
review portals are not well designed They change to [sic] frequently for sponsors. Very 
 
____________________ 
80. Deepak Chilkoti. 2019. “Chapter 25: Stakeholders, Resources, and Documents in Clinical Research.” In Clinical Pharmacy 




amateurish in their ease of use.”82 When asked to comment on the effectiveness of their 
relationship with sponsors and CROs, a respondent with dual roles as a PI and leader 
said, “Many are very responsive, some that are smaller organizations are less 
responsive.”83 A research staff member shared, “good and timely communication helps 
both parties in order to give the best care to the patients.”84 As sponsors and CROs 
navigate changing requirements with monitoring and safety reporting, when all 
stakeholders approach the partnership in the spirit of good communication, the patients 
ultimately benefit from transparent collaboration dedicated to process improvement. 
  7.2.6. Patient Focus. 
 The ultimate goal of researchers is to provide tangible benefit to the patients that 
volunteer their lives to participate in a clinical trial. As part of the informed consent 
process, patients are educated about what the potential risks of participation are, what 
their options are outside of research participation, and how there are many different  
teams that are overseeing the research conduct to ensure that their safety and rights 
are protected. A respondent holding a leadership and PI role exclaimed,  
I have had many patients get beneficial and life saving treatments way before 
FDA approval. In addition, the extra supervision provided by research staff, 
pharmacy and IRB makes this a much safer treatment than standard treatment, 
even when the drugs are very new.85 
 
Seeing these physicians engaged in the research process while holding the patient 
experience in the highest regard fosters a positive culture among other investigators 
and research staff. A research staff member shared,  
 
____________________ 
82. Questionnaire respondent, November 1, 2020. 
83. Questionnaire respondent, November 2, 2020. 
84. Questionnaire respondent, October 26, 2020. 




Caring about our community our patients our department and team members has 
been the number one key to my involvement and be part of studies that have 
been approved by the FDA which is now a standard of care option for our 
patients whom are currently living a better quality of life and at times longer than 
expected. I would say that is the most rewarding experience and benefit for our 
community and patients.86 
 
For many years cancer patients and their caregivers have formed organizations 
that offer support to patients and their families. Many of these offer emotional support, 
financial resources, and assistance in finding clinical trials that patients can hopefully 
participate in. Some organizations are devoted to a specific cancer type, or offer help for 
a certain population. An exciting development in the clinical research world is seeing 
patients themselves advocating for changes to how research is conducted. According to 
Wingfield, who was himself a research participant-turned IRB professional,  
We gave input on whether we thought the research was needed in our local 
community and if the design of the research was fair to the participants… We 
were not just a figurehead group to satisfy network funding requirements. Our 
opinions were actively sought and respected by the researchers in the clinics.87  
 
The clinical trials industry is now incorporating patient advocacy and feedback in clinical 
trial design on a large scale. The Patient-Centered Outcomes Research Institute 
(PCORI) is a cooperative research group that is conducting studies in the United States 
and Canada, and working to increase minority participation in clinical trials. Their 
mission states: 
PCORI helps people make informed healthcare decisions, and improves 
healthcare delivery and outcomes, by producing and promoting high-integrity, 
evidence-based information that comes from research guided by patients, 
caregivers, and the broader healthcare community.88 
 




86. Questionnaire respondent, October 26, 2020. 
87. Harry Wingfield. Human Subjects Research: An Insider’s View (Independently published, 2020), 31. 




projects… [they] also provide funding to help more patients and other stakeholders 
become involved in the research process.”89 Research professionals are embracing 
patient suggestions and including patients in the design of clinical trials. There is greater 
engagement of the patient population which has altered the very structure of how 
clinical research is conducted. The hope is that this will encourage clinical trial 
participation by inviting patients into a larger clinical trial community. 
7.2.7. Unilateral study initiation process does not verify sponsor 
qualifications. 
7.2.7.1. Propose a Sponsor Qualification Tool to Examine the 
Sponsor’s and CROs Ability to Support the Site Throughout the 
Conduct of the Clinical Trial. 
 When a sponsor or a site expresses interest in clinical trial collaboration, typically 
the parties sign a Non-disclosure agreement, to ensure confidentiality of the proprietary 
information that will be shared. Once this is signed, the sponsor can then share details 
of the study, and the site can decide if conducting the study is feasible at their center. 
Traditionally the sponsor conducts a Site Qualification Visit, where a sponsor or  
Contract Research Organization (CRO) representative conducts an in-person visit at 
the site, looking at the facilities, personnel, standard operating procedures, and 
determining if the site has the experience to meet the sponsor’s requirements 
throughout the trial. The author has facilitated many of these Site Qualification Visits at  
multiple institutions, guiding sponsor and CRO representatives through the different 
divisions of an oncology research practice.  
____________________ 




As described, the pre-contract trial qualification process is unilateral- there has  
 
been no sponsor qualification conducted to determine if the sponsor’s infrastructure 
would adequately support the site throughout the conduct of the trial. The author 
proposes a Sponsor Qualification Tool90 (please see Appendix 3. Sponsor Qualification 
Tool) to allow sites to assess whether the sponsor has the expertise to run a clinical trial 
before they execute an agreement to accept a research protocol. The tool is separated 
into categories including Sponsor demographics, Contractual & Financial Terms, CRO 
oversight, and Trial execution. Trial execution includes the sub-categories Recruitment, 
Equipment, and Protocol assessments. 
 The initial items on the tool will ask for general information, such as the study 
name, study number, and study chair. The investigational product and IND number, and 
indication under study are also requested. An important question to ask is who is 
supplying the investigational product? Is it supplied by the sponsor, or sourced via 
commercial supply? The form also asks for the name of the sponsor, a name of the 
sponsor representative, and contact information. Sponsor demographics will inquire 
how many studies they have conducted with the study cancer, how many Investigational  
New Drug (IND) approvals do they hold for the indicated cancer, and how many New 
Drug Applications (NDA) have been filed with the FDA in the last 5 years. How many 
studies have they attempted for this particular investigational product? Have they been 
inspected by the FDA and what was the outcome? Was the FDA inspection ‘for cause’ 
or ‘routine’? 
The Contractual & Financial Terms section covers general contractual terms. The  
____________________ 




questions on the assessment include: 
  
 1. Who are the key personnel required on the study? 
 2. What are your deliverables? 
 3. How often do you pay sites?  
 4. What is your indemnification policy? 
 5. What is your data ownership policy? 
 6. What is your intellectual property policy (including patent and copyright  
material)? 
7. What is the average length of time to finalize contract negotiations? 
8. Will a final budget be available prior to contract negotiations? 
9. Which procedures is the sponsor considering Ordinary Care/ Standard of Care 
that Medicare may not cover? 
 
The purpose of these questions is to pre-empt any terms that may not be acceptable to 
the site, allowing the site to have an opportunity to decide if any of those terms warrant 
negotiation prior to contract execution. 
 The CRO Oversight questions are intended to evaluate the potential CRO that is 
contracted to assist the site with study conduct: 
 1. How many studies has the CRO conducted on the study cancer? 
 2. What is the rate of Clinical Research Associate (CRA) turnover in the last 3  
years? 
 2a. On average how many monitors have been assigned to a single study  
in the last 3 years? 
 3. Will monitors conduct remote Site Initiation Visits (SIV) and Interim monitoring  
visits (IMV)? 
 4. Has the CRO successfully conducted virtual SIVs and IMVs? 
Note: The institution will not allow source documentation to be uploaded to 
any external document repository. The institution will provide cloud-based 
document storage that study monitors can securely access. 
 5. What is the Electronic Data Capture (EDC) program? 
 6. Will the CRO hold periodic meetings for PIs or study coordinators? 
 
 The following section of the Sponsor Qualification Tool is for Trial execution. The 
recruitment questions include: What is your expected annual subject accrual rate? What 
recruitment materials are provided? Will document translation (for Informed Consents 
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and protocol-required assessments) be paid by the sponsor? If a translated Informed 
Consent form is not available, can the site use a Short Form Consent Form?  
The Equipment section will include: What equipment will the sponsor provide? 
What facilities and equipment do you expect from the recruiting site? The Protocol 
Assessments section will include the following: Are there central assessments? Please 
indicate all that apply: Laboratory, Imaging, Disease Response Assessment, and other. 
The questions above serve as a starting point for the sponsor and CRO to be 
more forthcoming regarding their capabilities prior to initiating a clinical trial. The hope is 
to empower research sites to ask sponsors and CROs questions and determine if their 
site’s needs can be met during study initiation and study recruitment, finding effective 
resolution of issues with the investigational product and adverse events, and periodic 




Chapter 8. Conclusion 
The author examined the connection between stakeholders involved in the 
clinical research enterprise, and their respective roles and goals. These stakeholders 
include the sponsor, contract research organizations, principal investigators, and the 
research institution. At the center of the complementary entities are the patients that put 
their trust in the clinical research system to give themselves hope, and contribute to and 
advocate for clinical research. Adult oncology Principal Investigators, Leaders, and 
Research Staff at the author’s community hospital research practice graciously 
contributed to the conduct of this Capstone Project. There were areas identified for 
further investment within the institution’s clinical research infrastructure. The author has 
offered operational enhancements for the institution and created a Sponsor Qualification 
Tool that will empower clinical research sites to determine if a sponsor and CRO are 
suitable for a productive and symbiotic partnership. 
The need for biomedical innovation has accelerated, and the need for research 
sites that can contribute quality data and sponsors that can design meaningful science 
is ever-growing. Research institutions with unestablished or inefficient research 
infrastructure can benefit from knowledge of stakeholder relationships and the risks of 
misconduct from sponsors, CROs, PIs, and the research institution itself. Risk mitigation 
and stakeholder engagement empower human subjects. 
In the history of clinical research there have been instances where actions 
among stakeholders have caused harm to patients and diminished trust in the scientific 
community. As evidenced in the long-term changes to federal regulations and Good 
Clinical Practice guidance, the country’s regulatory authorities and the clinical research 
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industry have taken significant steps to reduce the risk of research misconduct. This 
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Appendix 1. Questionnaire 
 
INTRODUCTION 
I am Carolina, research coordinator in Adult Radiation Oncology and Neuro Oncology. 
This questionnaire is on goals and expectations that clinical trial research stakeholders 
at Research sites may experience. By completing this questionnaire, you are 
consenting to participate in this project. Your participation is voluntary and you can stop 
at any time and skip any questions. This questionnaire should not take more than 10 
minutes of your time. 
For the purposes of this questionnaire, a Research site is an institution where Human 
Subjects research is conducted.1 A sponsor is the organization or investigator “who 
initiated the study and who has authority and control over the study.”2 A contract 
research organization is “a company hired by another company or research center to 
take over certain parts of running a clinical trial. The company may design, manage, 
and monitor the trial, and analyze the results.”3   
The feedback you provide will be used in support of the Capstone Project I am 
completing as a requirement for the Master of Science in Research Administration at 
Johns Hopkins University. Your responses are anonymous and will be analyzed for this 
Capstone Project. 
If you have any questions or concerns regarding this Questionnaire, please contact me 
at cmancho1@jh.edu. If you have concerns or complaints about the research, or 
questions about your rights as a research subject, please contact the Orlando Health 
IRB at (321) 841-5895. 
I greatly appreciate your time. 
1. How long have you worked in clinical research?  
☐ 11+ years  
☐ 6-10 years 
☐ 2-5 years 
☐ 0-1 year 
______________ 
1. 45 CFR 46.102 
2. Glossary of Common Site Terms, s.v. “Sponsor,” accessed September 18, 2020, https://clinicaltrials.gov/ct2/about-
studies/glossary. 





2. What is your role at your institution? Select all that apply 
☐ Leadership  
☐ Clinical/ Principal Investigator 
☐ Research Staff 
 
3. My institution provides effective training on how to perform my role 




☐ Strongly Disagree  
 
4. I feel pressure to enroll more patients into clinical trials 




☐ Strongly Disagree 
☐ Not Applicable 
 
5. I feel pressure to get investigational drugs/ devices/ doses approved for ordinary care




☐ Strongly Disagree 
☐ Not Applicable 
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6. I have had concerns about clinicians pursuing off-label usage of drugs without IRB 
and FDA oversight 




☐ Strongly Disagree 
 
7. I feel pressure to complete tasks unrelated to conducting or reviewing research 
☐ Always 




☐ Not Applicable 
 
8. I receive effective protocol-specific training from external research partners 
(Sponsors or Contract Research Organizations) 




☐ Strongly Disagree 






9. External research partners (Sponsors or Contract Research Organizations) are 
responsive to my site’s needs 
☐ Always 





10. Patient needs outweigh the need to adhere to the research protocol, even if it leads 
to a deviation 




☐ Strongly Disagree 
☐ Not Applicable 
 
11. My site has effective research partnerships that ultimately benefit the patient 




☐ Strongly Disagree 
 
Please feel free to comment on the effectiveness of your relationship with external 





Please feel free to comment on any administrative challenges you encounter in your 
clinical research role: 
_______________________________________________________________ 
 












You are receiving this because you are an investigator, leader, or research staff within 
Adult Oncology Research or the Corporate Office of Research Operations. 
 
I am Carolina Manchola-Orozco CCRP, Clinical Research Coordinator in Adult 
Radiation & Neuro Oncology. I would greatly appreciate if you could complete and 
submit this questionnaire for my Capstone project as a requirement of a MS in 
Research Administration at Johns Hopkins University.  
 
Project Title:  
Clinical Research Stakeholders’ Goals and Expectations 
Principal Investigators: 
Johns Hopkins University – Marianne Woods PhD, JD 
Orlando Health – Naren Ramakrishna MD, PhD 
 
Attached is a link to a questionnaire that assesses your goals, expectations, and 
challenges as you conduct clinical research activities here and with Sponsors and 
Contract Research Organizations (CROs). This study will explore factors that may 
protect against research misconduct in your interactions with institutional staff, 




There are no direct benefits, and you will not be compensated for participating. Your 
participation is anonymous and voluntary, and you can skip any questions. Data will be 
collected and securely and confidentially stored via a Google Docs form. Neither your 
email address nor your IP address will be recorded. The Principal Investigator at Johns 
Hopkins and I will have access to your data for the purpose of data analysis and 
reporting. Completing this should take less than 10 minutes of your time.  
 
If you have any questions or concerns regarding this Questionnaire, please contact me 
at cmancho1@jh.edu. If you have concerns or complaints about the research, or 
questions about your rights as a research subject, please contact the Orlando Health 
IRB at (321) 841-5895. 
 
Thank you!  
 




Appendix 3. Sponsor Qualification Tool 
 
Sponsor Qualification Tool 
Please complete all of the questions below.  
If you have any questions please reach out to your Regulatory Coordinator: 
Name:______________________ Office #: ______________ Email: _______________________ 
Study Name: ___________________________________________________________________ 
Study Number: ________________________    Study Chair: _____________________________ 
Investigational Product: _________________    IND #:  _________________________________ 
Indication under study: _________________     Product Supplied by: ☐Sponsor  ☐Commercial 
Sponsor Name: _________________________________________________________________  
Sponsor Representative:__________________________________________________________ 
Sponsor Contact Information (telephone/ email): _____________________________________ 
Sponsor Demographics: 
1. How many studies have you conducted with the study cancer? ______ 
2. How many Investigational New Drug (IND) approvals do you hold for the indicated cancer? 
______ 
3. How many New Drug Applications have you filed with the FDA in the last 5 years? ______ 
4. How many studies have you attempted for this particular investigational product? ______ 
5. Have you been inspected by the FDA? Circle one:  Yes / No 
5a. If yes, what was the outcome? _________________________________________ 
5b. Why was the FDA inspection conducted? Circle one:  For Cause / Routine 
 
Contractual & Financial Terms: 
1. Who are the key personnel required on the study? ______________________________ 
__________________________________________________________________________ 
2. What are your deliverables? _________________________________________________ 
3. How often do you pay sites? _________________________________________________ 
4. What is your indemnification policy? __________________________________________ 
__________________________________________________________________________ 
5. What is your data ownership policy? __________________________________________ 
__________________________________________________________________________ 





7. What is the average length of time to finalize contract negotiations? ______ months 
8. Will a final budget be available prior to contract negotiations? Yes / No 
9. Which procedures are the sponsor considering Ordinary Care/ Standard of Care that 
Medicare may not cover? ___________________________________________________ 
________________________________________________________________________ 
CRO Oversight: 
1. How many studies has the CRO conducted on the study cancer? ______ 
2. On average how many monitors have been assigned to a single study  
                 in the last 3 years? ______ 
3. Will monitors conduct remote Site Initiation Visits (SIV) and Interim monitoring Visits 
(IMV)? Circle one: Yes / No 
4. Has the CRO successfully conducted virtual SIVs and IMVs? 
Note: The institution will not allow source documentation to be uploaded to 
any external document repository. The institution will provide cloud-based 
document storage that study monitors can securely access. 
5. What is the Electronic Data Capture (EDC) program? _______________________ 
6. Will the CRO hold periodic meetings for PIs or study coordinators? Circle one: Yes / No 
 
Trial Execution: 
1. What is your expected annual subject accrual rate? ______ per year 
2. What recruitment materials are provided? ______________________________________ 
___________________________________________________________________________ 
3. Will document translation (for Informed Consents and protocol-required assessments) be 
paid by the sponsor? Circle one: Yes / No 
4. If a Consent Form is not available, can the site use a Short Form? 
Circle one: Yes / No 
 
Equipment: 
1. What equipment will the sponsor provide? ______________________________________ 
___________________________________________________________________________ 




1. Are there Central assessments? Circle one: Yes / No 
If Yes, please indicate all that apply: 
☐ Laboratory               ☐ Disease Response Assessment 
☐ Imaging                    ☐ Other: ________________________________________________ 
 
Thank you for completing the Sponsor Qualification Tool. 
Name of person completing form: ___________________ Contact information: _____________ 





For Internal Use: 
Internal Reviewer: _______________________ 
Date: ______________ dd/mmm/yyyy 
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